Format

Send to:

Choose Destination
See comment in PubMed Commons below
Curr Opin Lipidol. 2009 Aug;20(4):282-7. doi: 10.1097/MOL.0b013e32832ca1d6.

Targets for LDL-lowering therapy.

Author information

  • 1Mike Rosenbloom Laboratory for Cardiovascular Research, McGill University Health Centre, Royal Victoria Hospital, Montreal, Quebec, Canada. allansniderman@hotmail.com

Abstract

PURPOSE OF REVIEW:

To compare non-HDL-cholesterol (non-HDL-C) and apolipoprotein B (apoB) as targets for LDL-lowering therapy. The conventional approach is restricted to a comparison of in-trial data. Although essential, this overlooks the issue as to which marker better identifies residual risk after any particular treatment regimen.

RECENT FINDINGS:

Data from a series of recent studies, including Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin, Measuring Effective Reductions in Cholesterol Using Rosuvastatin Therapy II, Treating to New Targets-Incremental Decrease in End Points Through Aggressive Lipid Lowering and Collaborative Atorvastatin Diabetes Study, demonstrating that apoB better identifies residual risk than non-HDL-C will be reviewed.

SUMMARY:

Comparing markers such as non-HDL-C and apoB for the accuracy with which they identify risk during a trial is essential but not sufficient. It is also necessary to compare markers for how well they identify residual risk, and, in this regard, apoB clearly outperforms non-HDL-C.

PMID:
19474729
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Write to the Help Desk